Thomas Weimer

USPTO Granted Patents = 27 (Patent Applications = 17)

CIPO Patents = 6 (Patent Applications = 7)

EPO Patents = 24 (Patent Applications = 19)

Average Co-Inventor Count = 4.0

ph-index = 7

Forward Citations = 205(Granted Patents)

Company Filing History:

Csl Behring Lengnau Ag

Years Active: 2001-2024

Loading Chart...

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11890327 - Truncated von Willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder (2024-02-06),

2. 11814421 - Truncated von Willebrand Factor polypeptides for treating hemophilia (2023-11-14),

3. 11564976 - Methods for preparing modified von Willebrand Factor (2023-01-31),

4. 11155601 - Modified von Willebrand factor having improved half-life (2021-10-26),

5. 11141466 - Modulation of FVIII immunogenicity by truncated VWF (2021-10-12),

6. 10905747 - Methods for preparing modified von Willebrand factor (2021-02-02),

7. 10772936 - Methods for preparing modified von Willebrand factor (2020-09-15),

8. 10688157 - Truncated von Willebrand factor polypeptides for treating hemophilia (2020-06-23),

9. 9878017 - Covalent complex of von Willebrand Factor and factor VIII, compositions, and uses relating thereto (2018-01-30),

10. 9458223 - Von willebrand factor variants having improved factor VIII binding affinity (2016-10-04),

11. 9347051 - Coagulation factor X polypeptides with modified activation properties (2016-05-24),

12. 9290561 - Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life (2016-03-22),

13. 9249404 - Coagulation factor X polypeptides with modified activation properties (2016-02-02),

14. 8828939 - Modified vitamin K dependent polypeptides (2014-09-09),

15. 8765915 - Modified coagulation factor VIIa with extended half-life (2014-07-01),

Title: Thomas Weimer: Innovator in Blood Coagulation Therapies

Introduction

Thomas Weimer, an accomplished inventor based in Gladenbach, Germany, has made significant contributions to the field of blood coagulation therapies, holding an impressive portfolio of 27 patents. His innovations are focused on developing advanced treatments for blood coagulation disorders, particularly concerning the von Willebrand factor and Factor VIII.

Latest Patents

Weimer's recent patents showcase his dedication to addressing complex medical issues. One of his notable inventions is a recombinant polypeptide comprising a truncated von Willebrand factor for the extravascular administration in the treatment or prophylaxis of blood coagulation disorders. This invention involves administering the recombinant polypeptide alongside a Factor VIII protein, highlighting the importance of the molar ratio which must be higher than 50 for effective treatment.

Another key patent pertains to a polypeptide that includes a truncated von Willebrand factor and a half-life extending moiety. This invention aims to treat hemophilia by increasing the endogenous Factor VIII levels in patients with a historically reduced activity level of this critical protein. The polypeptide is designed to bind to the endogenous FVIII, evidencing Weimer's focus on enhancing patient outcomes in those suffering from hemophilia.

Career Highlights

Throughout his career, Thomas Weimer has been affiliated with prominent companies such as CSL Behring GmbH and CSL Behring Lengnau AG. His work at these organizations has been pivotal in advancing therapeutic solutions for blood coagulation disorders, reflecting his skill and expertise in the biotechnology sector.

Collaborations

Weimer's journey has been supported by collaborations with esteemed colleagues, including Stefan Schulte and Wiegand Lang. Their combined efforts contribute to the innovative research and development in the treatment of blood coagulation disorders, underscoring the significance of teamwork in scientific advancements.

Conclusion

Thomas Weimer's contributions to the field of blood coagulation therapies through his extensive patent portfolio demonstrate his dedication to improving patient care. As he continues to innovate, his work holds promise for the future of treatment options available for individuals with blood coagulation disorders.

This text is generated by artificial intelligence and may not be accurate.